

## **Supplementary Information**

### **Association of *TP53* alteration with tissue specificity and patient outcome of *IDH1*-mutant glioma**

Balazs Murnyak<sup>1</sup> and L. Eric Huang<sup>1,2</sup>


<sup>1</sup>Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah 84132, USA

<sup>2</sup>Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, USA


**Corresponding Author:** L. Eric Huang, Department of Neurosurgery, Clinical Neurosciences Center, 175 North Medical Drive East, Salt Lake City, UT 84132, USA.

Phone: +1 801-535-3221


E-mail: [eric.huang@hsc.utah.edu](mailto:eric.huang@hsc.utah.edu)




**Supplementary Figure S1.** Distinctive distribution of *IDH1*, *IDH2*, and *TP53* alterations in Non-Redundant. Extraction of *IDH1*, *IDH2*, and *TP53* alterations revealed extremely high frequency of *IDH1* mutations exclusively in lower-grade glioma (A) in contrast with low frequencies of *IDH2* amplification and mutation (B) and high frequencies of *TP53* alterations (C) in various cancer types. The cutoff is 5% for *IDH1* and *IDH2* and 60% for *TP53*.



**Supplementary Figure S2.** Rare co-occurrence of *IDH2* hotspot mutation and *TP53* alteration in human cancer. Cancer types harboring *TP53* alterations are extracted in correspondence to concurrent *IDH2* hotspot mutations from TCGA\_PanCancer (A), MSK\_Impact (B), and Non-Redundant (C). Sample counts of the cancer types are presented in reference to specific types of *IDH2* mutation.



**Supplementary Figure S3.** Higher frequencies of co-occurrence of specific *IDH1* mutation and *TP53* alteration in glioma. Glioma and non-glioma were compared for their co-occurrence frequencies of specific *IDH1*<sup>R132X</sup> and *TP53* alteration. \* $p < 0.05$ ; \*\* $p < 0.01$ .



**Supplementary Figure S4.** *IDH1* status and *TP53* status distinguish patient survival in lower-grade glioma of TCGA\_PanCancer. *IDH1* status was analyzed for overall survival (A). *TP53* status was analyzed for overall survival (B) and in the *IDH1* wildtype subgroup (C). Two-tailed  $p$  values are specified.